CVRX NASDAQ
CVRx, Inc.
1W: +5.8%
1M: -23.9%
3M: -0.7%
YTD: -14.5%
1Y: -13.2%
3Y: -50.0%
$6.11
+0.04 (+0.66%)
Weekly Expected Move ±16.7%
$4
$5
$6
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (40)
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx signals $63M-$67M 2026 revenue outlook as Category I CPT transition reshapes prior authorization dynamics
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx (CVRX) Q1 2026 Earnings Call Transcript
CVRx Reports First Quarter 2026 Financial and Operating Results
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of “Moderate Buy” from Analysts
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
CVRx sees Q1 revenue in the range of $14.7M to $14.8M
CVRx, Inc. Investigated by the Portnoy Law Firm
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of “Moderate Buy” from Analysts
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
CVRX INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving CVRx Inc.
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm
CVRx INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. – CVRX
CVRx Kicks Off One Of The Largest Heart Device Trials In History
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of “Moderate Buy” by Analysts
CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CVRx (NASDAQ:CVRX) Stock Price Down 9.9% – Here’s What Happened
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of “Moderate Buy” by Analysts
CVRx (NASDAQ:CVRX) versus Bluejay Diagnostics (NASDAQ:BJDX) Critical Comparison
CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference